Medication-related osteonecrosis of the jaw: the radiologist's role.

Autor: Alemán Millares R; Departamento de Radiología, Hospital Ribera Povisa, Vigo, Pontevedra, Spain. Electronic address: raleman@povisa.es., Santos Armentia E; Departamento de Radiología, Hospital Ribera Povisa, Vigo, Pontevedra, Spain., Del Campo Estepar S; Departamento de Radiología, Hospital Ribera Povisa, Vigo, Pontevedra, Spain., Novoa Ferro M; Departamento de Radiología, Hospital Ribera Povisa, Vigo, Pontevedra, Spain.
Jazyk: angličtina
Zdroj: Radiologia [Radiologia (Engl Ed)] 2023 Sep-Oct; Vol. 65 (5), pp. 473-480. Date of Electronic Publication: 2023 Sep 09.
DOI: 10.1016/j.rxeng.2021.10.005
Abstrakt: In recent decades, the dreaded adverse effect of bisphosphonates, osteonecrosis of the jaw, has been widely reported and described in detail. Osteonecrosis of the jaw consists of the destruction of part of the maxilla as a consequence of these antiresorptive drugs. In recent years, new drugs that can also cause osteonecrosis of the jaw (e.g., some monoclonal antibodies or antiangiogenic drugs) have come on the market. For this reason, the term "bisphosphonate-related osteonecrosis of the jaw" has been replaced with "medication-related osteonecrosis of the jaw (MRONJ). This review aims to describe the radiologic characteristics of MRONJ that, although nonspecific, radiologists need to recognize in the appropriate clinical context.
(Copyright © 2021 SERAM. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: